Reporting period January – December

- **Orders received** increased by 24.1% to SEK 16,519 million (13,316)
- **Net sales** increased by 26.5% to SEK 16,445 million (13,001)
- **Profit before tax** amounted to SEK 1,775 million (1,728)
- **Net profit** amounted to SEK 1,261 million (1,259)
- **Earnings per share** amounted to SEK 6.24 (6.21)
- **Dividend per share** proposed at SEK 2.40 (2.20)
- **Acquisition of Boston Scientific's** cardio and vascular surgery divisions
- **The Board of Getinge AB** proposes a new share issue of approximately SEK 1,500 million for financing and continued expansion.
- **New financial targets**

Fourth quarter

- **Orders received** increased organically by 5.5%
- **Net sales** increased by 29.1% to SEK 5,157 million (3,995)
- **Operating profit (EBITA) before restructuring** increased by 29.2 % to SEK 1,096 million (848)

Fourth quarter 2007

Orders received

Demand for the Group's products remained favourable in most markets. During the quarter, orders received grew organically by 5.5%. The volume trend was highly favourable in regions outside Western Europe. The weaker orders received in Europe are to be viewed in light of the very positive orders received in Europe in the same period last year.

For Medical Systems, orders received increased organically by a healthy 5.1% compared with a highly successful fourth quarter 2006. Growth was particularly strong in emerging markets. The business area saw a number of major orders in emerging markets postponed to the current year.

The organic increase in orders received for the Extended Care business area amounted to 4.1%. Volume growth remained strong in North America, although was slightly weaker in Western Europe.

Infection Control's orders received for the quarter grew organically by 6.9%. Very strong orders received in North America contributed to the growth in volume.

Results

Consolidated profit before tax for the period amounted to SEK 902 million (788), an increase of 14.5%. EBITA excluding restructuring costs increased by 29.2% and amounted to SEK 1,096 million (848). The EBITA margin improved further and for the full-year amounted to 16.3%, an increase in line with announced margin improvements.

Consolidated operating cash flow increased by 23% compared with the same period in the preceding year and amounted to SEK 543 million.

Outlook

The demand situation for the Group's products is still considered to be very good in most geographic regions in which the Group operates. The Group's order book contains a high level of orders.

Medical Systems continues to expect to grow faster than the market for the current year. Growth is underpinned by a strong and innovative product portfolio and by a strengthened market organisation. A continued focus on production in China and Turkey is strengthening long-term competitiveness.

Infection Control also anticipates continued strong growth in invoicing. The launch of several new products and extended market presence, primarily in the Far East, will contribute to volume growth.

In Extended Care, volume growth is expected to improve compared with the level in 2007. At the same time, restructuring costs are declining and the synergies from the Huntleigh integration are becoming more visible in the business area's earnings. The main emphasis of the Huntleigh integration will remain on the cost structure for the beginning of 2008, but will be increasingly focused on revenue synergies in the latter half of the year.

The acquisition of Boston Scientific's cardio and vascular surgery divisions will be consolidated in the Group from 1 January 2008 and, excluding integration costs, are expected to contribute to both consolidated profit before tax and to the continued expansion of the consolidated EBITA margin.

On the whole, the Group expects organic invoicing growth in line with 2007 levels. The EBITA margin will continue to be strengthened, even excluding the acquisition of the cardio and vascular surgery divisions from Boston Scientific. Exchange-rate changes will negatively impact earnings for the current year.

The tax rate for the current year will improve by 1 percentage point and amount to 28%.

Revised financial targets for the Getinge Group

With respect to the acquisition of Boston Scientific's cardio and vascular surgery divisions, the Group's financial targets regarding the EBITA margin were reviewed. The new target for the consolidated EBITA margin is 18-19%, compared with the previous level of 17%. The corresponding adjustment of the EBITA margin for the Medical Systems business area is a target of 19-20%, compared with the previous level of 17%. Given the current circumstances and Group structure, the target at Group level is expected to be realised in the financial year 2009.

Business area Medical Systems

Market development

Orders received per market	**2007 Q 4**	2006 Q 4	*Change adjusted for curr.flucs.&corp.acqs.*	**2007 12 Mon**	2006 12 Mon	*Change adjusted for curr.flucs.&corp.acqs.*
Europe	**895**	897	*-1,1%*	**3 361**	3 316	*1,6%*
USA and Canada	**306**	377	*-12,2%*	**1 063**	1 289	*-10,8%*
Asia and Australia	**317**	221	*47,4%*	**1 058**	852	*29,4%*
Rest of the world	**125**	90	*34,4%*	**419**	378	*10,2%*
Business area total	**1 643**	1 585	*5,1%*	**5 901**	5 835	*3,5%*

Orders received grew organically by 5.1% compared with the strong fourth quarter in the preceding year. Orders received in the BRIC markets were highly favourable despite the postponement of several large orders until 2008. Growth in orders in the Japanese market also contributed to the positive trend.

In Europe, orders received were in line with the strong quarter in the preceding year. Orders received declined in German-speaking markets where the change in value-added tax in the fourth quarter of the preceding year contributed to strong orders received in 2006. In the UK, orders received rose marginally, while growth in other markets was moderate.

Orders received in North America fell during the quarter, which was primarily attributable to Surgical Workplaces that had very strong orders received during the same quarter in the preceding year.

Results

	2007 Q 4	2006 Q 4	Change	2007 12 Mon	2006 12 Mon	Change
Net sales, SEK million	**1 949**	1 681	*15,9%*	**6 079**	5 542	*9,7%*
adjusted for currency flucs.& corp.acqs			*18,0%*			*12,2%*
Gross profit	**957**	870	*10,0%*	**3 112**	2 784	*11,8%*
Gross margin %	***49,1%***	*51,8%*	*-2,7%*	***51,2%***	*50,2%*	*1,0%*
Operating cost, SEK million	**-547**	-544	*0,6%*	**-2 079**	-1 894	*9,8%*
EBITA before restructuring and integration costs	**412**	327	*26,0%*	**1 040**	896	*16,1%*
EBITA margin %	***21,1%***	*19,5%*	*1,6%*	***17,1%***	*16,2%*	*0,9%*
Restructuring and integration costs	**–**	–	*0,0%*	**–**	–	*0,0%*
EBIT	**410**	326	*25,8%*	**1 033**	890	*16,1%*
EBIT margin %	***21,0%***	*19,4%*	*1,6%*	***17,0%***	*16,1%*	*0,9%*

Medical Systems' EBITA increased by a highly favourable 26% during the quarter and for the full-year amounted to SEK 1,040 million. This growth in earnings is primarily an effect of the robust invoicing volume in which the final invoices for major projects for Russia were sent during the period, which also explains why the gross margin was lower in the quarter. The EBITA margin amounted to an encouraging 21.1% in the period and to 17.1% on a full-year basis, which is in line with the business area's current operating margin targets.

Activities

Boston Scientific

The acquisition of Boston Scientific's cardio and vascular divisions, which was announced during the quarter, was completed on 7 January after the end of the reporting period. This also means that the operations will be consolidated in the earnings for the Getinge Group from January 2008.

The cardio surgery division with sales of approximately USD 189 million is a global leader in the areas of Endoscopic Vessel Harvesting, instruments for open surgery on beating hearts and products for anastomosis where blood vessels are connected surgically. About 90% of sales are to customers in the US through a direct sales organisation of 90 sales representatives. The headquarters are situated in San Jose, California, where the 90 person-strong product-development team is located. The manufacturing operation, which primarily specialises in assembly and quality assurance, is located in Dorado, in Puerto Rico.

The vascular surgery division with sales of approximately USD 84 million specialises in providing grafts for replacing diseased or damaged blood vessels in patients. The division is a global leader in grafts for treating aortic and thoracic aneurysms. Product development and manufacturing are situated in Wayne, in New Jersey.

The divisions, which had combined sales of USD 273 million in 2006, are highly profitable and had an EBIT margin of 26.4% in 2006.

This acquisition is part of Medical Systems' endeavour to strengthen its presence in the cardio and vascular surgery market, in which the business area has previously had a presence with its Cardiopulmonary division. The acquisition is expected to generate significant revenue synergies in the long term since the operations strongly complement the Cardiopulmonary division both in terms of geography and product range. In conjunction with the acquisition, the name of the Cardiopulmonary division was changed to Cardiovascular to better reflect the future operations.

Medical Systems envisages major opportunities to build a significant business in primarily the area of cardio surgery through additional acquisitions and own development. The market for cardio surgery products and implants amounts to more than USD 2.5 billion, while at the same time few of the major market players in the cardiovascular surgery area have prioritised this sub-market.

Product development

Medical Systems is currently experiencing a highly expansive phase in terms of product development and product launches.

The launch of Critical Care's new ventilator NAVA (Neurally Adjusted Ventilatory Assist) is proceeding according to plan. Customer and user reactions remain highly positive from reference hospitals across Europe. The business area anticipates that in the future it will be possible to demonstrate that NAVA shortens the duration of medical treatment and enhances the quality of care.

In Critical Care, efforts to develop a new generation of anaesthesia machines that can successfully compete in terms of both clinical performance and cost-efficiency are also proceeding according to plan. FLOW-i as the product family is named was exhibited at the Medica trade fair in the fourth quarter and initial customer feedback was very positive. The official launch of FLOW-i will take place at the large anaesthesia conference ESA in June 2008. Medical Systems' goal is to capture a significant share of the global anaesthesia market in the long term, which is valued at slightly more than EUR 560 million.

Regarding Cardiovascular (formerly Cardiopulmonary), significant drives in product development are being conducted in the Perfusion area. The work on producing a new generation of oxygenators has been under way for some time. The new oxygenator will be modular, allowing a number of new applications even outside the cardiopulmonary area, particularly in acute medicine and intensive care. The launch of a new generation of oxygenators will be completed in 2008 and will entail both improved clinical performance and significant cost reductions.

Production in China

As previously announced, a new production unit is being constructed in Suzhou, China. The unit is expected to be deployed at the beginning of the second quarter and will initially focus on the production of ceiling service units for operating theatres. Production of surgical tables will commence later in the year. The intention is that the unit will supply ceiling service units and surgical tables to both the Chinese and global markets.

New US organisation for Surgical Workplaces and Infection Control

Effective 1 January 2008, Getinge Inc, which has historically represented products from Medical Systems and Infection Control, will be reorganised. In the future, Getinge Inc will be a streamlined Infection Control company, focusing on Hospitals and Life Science customers. The Surgical Workplaces division will be transferred to Medical Systems' sales company Maquet Inc in New Jersey. The new organisation will better reflect the global structure of the overall organisation of Getinge's business areas, at the same time as it is considered important to combine the future anaesthesia launch with other products intended for operating theatre environments. The potential for strengthening market positions in Surgical Workplaces in the US is deemed to be immense and the aim is to double market shares from today's level of about 15% to 30% in the next few years.

Business area Extended Care

Market development

Orders received per market	**2007 Q 4**	2006 Q 4	*Change adjusted for curr.flucs.&corp.acqs.*	**2007 12 Mon**	2006 12 Mon	*Change adjusted for curr.flucs.&corp.acqs.*
Europe	**1 086**	576	*-0,7%*	**3 818**	1 948	*5,1%*
USA and Canada	**464**	285	*11,6%*	**1 692**	1 130	*4,8%*
Asia and Australia	**142**	27	*20,4%*	**500**	101	*6,0%*
Rest of the world	**19**	0	*0,0%*	**114**	2	*17,7%*
Business area total	**1 711**	888	*4,1%*	**6 124**	3 181	*5,0%*

The business area's orders received increased organically by 4.1% during the final quarter of the year.

In Europe, orders received were comparable with the final quarter of the preceding year. The changed value-added tax that favourably impacted orders received in German-speaking markets in the preceding year entailed a decline for the period. Order received rose in the UK and Scandinavia, while orders received remained stable or slightly falling in other markets in Europe.

In North America, orders received are continuing to perform positively in both Canada and the US.

Results

	2007 Q 4	2006 Q 4	Change	2007 12 Mon	2006 12 Mon	Change
Net sales, SEK million	**1 734**	893	*94,2%*	**6 009**	3 183	*88,8%*
adjusted for currency flucs.& corp.acqs			*10,9%*			*3,4%*
Gross profit	**818**	450	*81,8%*	**2 775**	1 500	*85,0%*
Gross margin %	***47,2%***	*50,4%*	*-3,2%*	***46,2%***	*47,1%*	*-0,9%*
Operating cost, SEK million	**-461**	-234	*97,0%*	**-1 894**	-977	*93,9%*
EBITA before restructuring and integration costs	**387**	219	*76,7%*	**998**	538	*85,5%*
EBITA margin %	***22,3%***	*24,5%*	*-2,2%*	***16,6%***	*16,9%*	*-0,3%*
Restructuring and integration costs	**-27**	5,0	*0,0%*	**-257**	-35	*0,0%*
EBIT	**330**	221	*49,3%*	**624**	488	*27,9%*
EBIT margin %	***19,0%***	*24,7%*	*-5,7%*	***10,4%***	*15,3%*	*-4,9%*

Extended Care's EBITA before restructuring and integration costs increased by an encouraging 76.7% and amounted to SEK 387 million (219). The growth in EBITA during the period is mostly attributable to the Huntleigh acquisition, although the earnings trend for the older operations remains favourable. The low gross margin for the period is an effect of the Huntleigh acquisition which on average reports lowers gross margins. Restructuring costs pertaining to the Huntleigh acquisition amounted to SEK 27 million during the quarter.

The EBITA margin excluding restructuring costs, which amounted to 16.6% for the full-year, improved compared with the pro forma margin for 2006 of 14.4%.

Activities

Huntleigh PLC integration

The integration of Huntleigh, which characterised much of the business area's activities in 2007, has largely been completed, meaning that the integration took place at a higher tempo than originally announced.

Integration in 2007 primarily focused on realising potential cost synergies. The focus on cost synergies will remain a priority at the beginning of 2008. Revenue synergies will be prioritised from the second half of 2008.

Regarding marketing activities, Extended Care's and Huntleigh's sales companies in all markets except for the US and the UK were integrated under joint management for each market in 2007.

Production restructuring that was implemented and announced entailed that a key portion of Huntleigh's production that was located in the UK and the US was transferred to a new facility in Poland. In mid-January 2008, the business area commenced negotiations with employee representatives regarding the transfer of the remaining production in Luton to China, and manufacturing at the unit in Ipswich to Poland. The new, joint brand strategy was introduced in the final quarter of 2007.

Outstanding integration projects that are expected to be implemented over the forthcoming two-year period are the coordination of the IT structure for both of the operations resulting in additional efficiency gains, and streamlining and outsourcing logistics to a third party.

As was announced earlier, the activities carried out are expected to lead to cost savings exceeding SEK 300 million annually, with full effect from 2009. The cost to fully implement the integration program is estimated to total approximately SEK 400 million, of which SEK 257 million is charged against earnings for 2007. The remainder of the restructuring costs are expected to be mainly charged against earnings for 2008.

Production in China

During the period, a decision was made to establish a production unit in China for Extended Care. This unit will be built on the Group's "campus" in Suzhou where Infection Control and Medical Systems are already located. The production unit will be completed at the end of the third quarter of 2008. Production at the new unit will initially focus on manufacturing pump units for wound-care mattresses, which are currently manufactured at the production unit in Luton in the UK.

Product developments and launches

Extended Care is continuing to increase investments in the development of new products in a bid to strengthen the growth and competitiveness of the business area. Between 15 and 20 new product launches and major product upgrades are planned for 2008.

The introduction of the business unit's NPWT (Negative Pressure Wound Therapy) product, Wound Assist, is proceeding according to plan. Marketing activities are currently being conducted toward a large number of customers in the UK and Germany, who will serve as reference customers for the continued development of products and concepts. Extended Care intends to establish a significant position in the growing European market in the next few years. A decision has not yet been made regarding any launches in the US. The wound-care market for NPWT technology is the fastest growing sub-market in wound-care and is expanding by 10-15% per year. The global market totals nearly SEK 8 billion.

Business area Infection Control

Market development

Orders received per market	**2007 Q 4**	2006 Q 4	*Change adjusted for curr.flucs.&corp.acqs.*	**2007 12 Mon**	2006 12 Mon	*Change adjusted for curr.flucs.&corp.acqs.*
Europe	**589**	589	*-0,6%*	**2 414**	2 236	*8,1%*
USA and Canada	**474**	393	*30,6%*	**1 448**	1 449	*8,2%*
Asia and Australia	**157**	184	*-13,1%*	**546**	525	*6,4%*
Rest of the world	**11**	21	*-49,5%*	**86**	75	*23,4%*
Business area total	**1 231**	1 187	*6,9%*	**4 494**	4 285	*8,2%*

The business area's orders received increased organically by a healthy 6.9% during the quarter. Strong volume growth in North America, which includes both Canada and the US, compensated for weaker growth in other geographic markets.

In Europe, orders received were in line with the same quarter in the preceding year. Volumes are increasing in Benelux and falling in southern Europe. Orders received remained unchanged in other regions.

Excluding Japan which declined during the quarter, orders received in the markets outside North America and Europe were in line with the same quarter in the preceding year.

Results

	2007 Q 4	2006 Q 4	*Change*	**2007 12 Mon**	2006 12 Mon	*Change*
Net sales, SEK million	**1 474**	1 422	*3,7%*	**4 357**	4 262	*2,2%*
adjusted for currency flucs.& corp.acqs			*6,2%*			*5,6%*
Gross profit	**579**	556	*4,1%*	**1 659**	1 605	*3,4%*
Gross margin %	***39,3%***	*39,1%*	*0,2%*	***38,1%***	*37,7%*	*0,4%*
Operating cost, SEK million	**-286**	-258	*10,9%*	**-1 034**	-1 043	*-0,9%*
EBITA before restructuring and integration costs	**297**	301	*-1,3%*	**640**	577	*10,9%*
EBITA margin %	***20,1%***	*21,2%*	*-1,1%*	***14,7%***	*13,5%*	*1,2%*
Restructuring and integration costs	**–**	-3	*0,0%*	**–**	-10	*0,0%*
EBIT	**293**	295	*-0,7%*	**625**	552	*13,2%*
EBIT margin %	***19,9%***	*20,7%*	*-0,8%*	***14,3%***	*13,0%*	*1,3%*

EBITA for the business area was in line with the preceding year and amounted to SEK 297 million (301). Invoicing growth was favourable as was the gross margin which benefited from a high and steady production volume. The higher expenses in the period pertain to the expansion of market activities. For the full-year, the EBITA margin amounted to 14.7%, which is a solid improvement compared with the preceding year when the EBITA margin was 13.5%.

Activities

New organisation in US

Similar to Medical Systems, Infection Control's US operations will also be streamlined, meaning that in the future Getinge Inc will be focused solely on customers in the hospitals and Life Science segment for infection control equipment. The decision to streamline the US organisation should be viewed in light of the organisational changes announced when Christer Ström assumed full responsibility for the business area on a global basis in September 2007.

Other information

Accounting

This interim report was prepared for the Group in accordance with the Annual Accounts Act and IAS 34 Interim Financial Reporting and for the Parent Company, in accordance with the Annual Accounts Act. The accounting and calculation principles used in the interim report are identical to those used in the most recent annual report.

Dividend

The Board and the President propose the payment of a dividend of SEK 2.40 (2.20) per share for 2007, amounting to SEK 484.5 million (444.1). The proposed record date will be 22 April 2008. VPC expects to pay the dividend to shareholders on 25 April 2008.

AGM

Getinge AB's Annual General Meeting will be held on 17 April 2008, at 4:00 p.m., in Kongresshallen, Hotel Tylösand, Halmstad, Sweden. The Annual Report for 2007 will be distributed to shareholders who request it not later than two weeks prior to the AGM. Shareholders who intend to participate at the AGM must be included in the shareholders' register maintained by VPC AB not later than 11 April 2008 and register their intention to participate with Getinge's head office not later than 11 April 2008.

New share issue

In respect to the previously announced acquisition of Boston Scientific's cardio and vascular surgery divisions and in order to create the financial strength required to take advantage of attractive acquisition opportunities in the short term, Getinge's Board of Directors has decided on a new share issue with preferential rights for Getinge shareholders of approximately SEK 1,500 million, on condition of the approval of an Extraordinary General Meeting.

Getinge is of the opinion that the favourable conditions for finding attractive acquisition opportunities will continue for the immediate future as a result of such matters as an excellent offering of attractive acquisition candidates in the medical technical market.

The proceeds of the issue are intended to repay part of the bank loan raised in conjunction with the acquisition of Boston Scientific's cardio and vascular surgical divisions, as well as to create financial scope for further business opportunities. It is assessed that the acquisition focus remains in the Medical Systems business area, with the aim of reinforcing the business area's market-leading position.

The Board intends to call an Extraordinary General Meeting in the near future with the aim of implementing the new share issue.

Risk management

Political decisions altering the healthcare reimbursement system represent the single greatest risk to the Getinge Group. The risk to the Group as a whole is limited by the fact that Getinge is active in a large number of countries. The Group's operational risks are limited, since as a rule its customers' operations are funded directly or indirectly from public funds. The Group's Risk Management team works continuously to minimise the risk of production disruptions.

Financial risk management

Getinge is exposed to a number of financial risks in its operations. “Financial risks” refer primarily to risks related to currency and interest rates as well as credit risks. Risk management is regulated by a financial policy established by the Board of Directors. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with Group management and the treasury function. The main financial risks to which the Group is exposed are currency risks, interest-rate risks, and credit and counterparty risks.

Events after year-end

The acquisition of the Boston Scientific divisions that commenced during the fourth quarter of 2007 was completed at the beginning of January 2008.

No other events of material significance took place after year-end.

Forward-looking information

This report contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.

Next report

The next report from the Getinge Group (first quarter of 2008) will be published on 17 April 2008.

Teleconference

A teleconference will be held today at 3:00 p.m. Swedish time. To participate, please call:
from Sweden: 08-50 520 114, password: Getinge
outside Sweden: +44 (0)20 7162 0125, password: Getinge

A recorded version of the conference will be available for five working days on the following numbers:
Sweden: +46 (0)8-505 203 33, access code: 780614
UK: +44 (0)20 7031 4064, access code: 780614

The Board of Directors and President ensure that the year-end report provides a true and fair overview of the Parent Company and the Group's operations, position and earnings and describes the material risks faced by the Parent Company and the Group.

Getinge, 28 January 2008

Carl Bennet *Chairman*	Johan Bygge	Rolf Ekedahl
Arild Karlsson	Carola Lemne	Margareta Norell Bergendahl
Bo Sehlin	Johan Stern	Johan Malmquist *CEO*

Getinge AB
Box 69, 310 44 Getinge
Telephone 035-15 55 00. Telefax 035-549 52
e-mail info@getinge.com
Corporate Registration Number 556408-5032
www.getingegroup.com

The information given here is information that Getinge AB is obligated to publish under the Securities Exchange and Clearing Operations Act and/or the Financial Instruments Trading Act.

Consolidated Income statement

SEK million	2007 Q 4	2006 Q 4	Change	2007 12 Mon	2006 12 Mon	Change
Net sales	**5 157**	3 995	*29,1%*	**16 445**	13 001	*26,5%*
Cost of goods sold [1]	**-2 802**	-2 120	*32,2%*	**-8 899**	-7 108	*25,2%*
Gross profit	**2 355**	1 875	*25,6%*	**7 546**	5 893	*28,1%*
Gross margin	*45,7%*	*46,9%*	*-1,2%*	*45,9%*	*45,3%*	*0,6%*
Selling expenses [1]	**-789**	-645	*22,3%*	**-3 072**	-2 467	*24,5%*
Administrative expenses [1]	**-430**	-311	*38,3%*	**-1 604**	-1 191	*34,7%*
Research & development costs [2]	**-70**	-70	*0,0%*	**-335**	-282	*18,8%*
Restructuring and integration costs	**-27**	2		**-257**	-45	
Other operating income and expenses	**-6**	-11	*-45,5%*	**4**	28	*-85,7%*
Operating profit [3]	**1 033**	840	*23,0%*	**2 282**	1 936	*17,9%*
Operating margin	*20,0%*	*21,0%*	*-1,0%*	*13,9%*	*14,9%*	*-1,0%*
Financial net	**-131**	-52		**-507**	-208	
Profit before tax	**902**	788	*14,5%*	**1 775**	1 728	*2,7%*
Taxes	**-261**	-215		**-514**	-469	
Net profit	**641**	573	*11,9%*	**1 261**	1 259	*0,2%*
Attributable to:						
Parent company's shareholders	**640**	571		**1 260**	1 254	
Minority interest	**1**	2		**1**	5	
Net profit	**641**	573		**1 261**	1 259	
Earnings per share, SEK [4]	**3,17**	2,83	*12,0%*	**6,24**	6,21	*0,5%*

1 Due to reclassification of certain costs, some transfers have been made in the comparision from cost of goods sold to selling- and administration expenses.

2 Development costs totalling SEK 313 (198) million have been capitalised during the year, of which 103 (70) million were capitalised during the quarter.

3 Operating profit is charged with

— amort. Intangibles on acquired companies	***-36***	*-10*	***-139***	*-37*
— amort. intangibles	***-27***	*-17*	***-82***	*-47*
— depr. on other fixed assets	***-126***	*-55*	***-463***	*-250*
	-189	*-82*	***-684***	*-334*

4 There are no dilutions

Quarterly results

SEK million	2005 Q 4	2006 Q 1	2006 Q 2	2006 Q 3	2006 Q 4	2007 Q 1	2007 Q 2	2007 Q 3	2007 Q 4
Net sales	3 888	2 975	3 148	2 883	3 995	3 415	4 029	3 844	5 157
Cost of goods sold	-2 163	-1 644	-1 726	-1 618	-2 120	-1 751	-2 206	-2 140	-2 802
Gross profit	1 725	1 331	1 422	1 265	1 875	1 664	1 823	1 704	2 355
Operating cost	-986	-1 020	-1 004	-898	-1 035	-1 264	-1 327	-1 351	-1 322
Operating profit	739	311	418	367	840	400	496	353	1 033
Financial net	-47	-49	-54	-53	-52	-114	-130	-132	-131
Profit before tax	692	262	364	314	788	286	366	221	902
Taxes	-197	-71	-98	-85	-215	-83	-106	-64	-261
Profit after tax	495	191	266	229	573	203	260	157	641

Consolidated Balance sheet

Assets SEK million	**2007 31 Dec**	2006 31 Dec
Intangible fixed assets	**10 396**	5 516
Tangible fixed assets	**2 327**	1 397
Financial assets	**755**	1 876
Stock-in-trade	**2 913**	2 083
Current receivables	**5 706**	4 332
Cash and cash equivalents	**894**	673
Total assets	**22 991**	15 877
Shareholders' equity & Liabilities		
Shareholders' equity	**6 623**	6 005
Long-term liabilities	**11 908**	6 568
Current liabilities	**4 460**	3 304
Total Equity & Liabilities	**22 991**	15 877

Consolidated Cash flow statement

SEK million	**2007 Q 4**	2006 Q 4	**2007 12 Mon**	2006 12 Mon
Current activities				
Operating profit	**1 033**	840	**2 282**	1 936
Adjustment for items not included in cash flow	**139**	65	**761**	277
Financial items	**-131**	-48	**-507**	-203
Taxes paid	**-131**	-79	**-528**	-387
Cash flow before changes in working capital	**910**	778	**2 008**	1 623
Changes in working capital				
Stock-in-trade	**247**	217	**-341**	-75
Rental equipment	**-43**	-9	**-168**	-11
Current receivables	**-1 106**	-794	**-458**	-484
Current operating liabilities	**171**	111	**287**	451
Cash flow from operations	**179**	303	**1 328**	1 504
Investments				
Acquisition of subsidiaries	**-44**	-33	**-5 622**	-272
Investments in intangible fixed assets	**-116**	-73	**-348**	-206
Investments in tangible fixed assets	**-130**	-110	**-467**	-315
Disposal of tangible fixed assets	**17**	5	**34**	157
Cash flow from investments	**-273**	-211	**-6 403**	-636
Financial activities				
Change in interest-bearing debt	**91**	947	**4 518**	568
Change in long-term receivables	**18**	-1 186	**1 249**	-1 277
Minority redemption	**–**	-3	**–**	51
Dividend paid	**0**	0	**-444**	-405
Cash flow from financial activities	**109**	-242	**5 323**	-1 063
Cash flow for the period	**15**	-150	**248**	-195
Cash and cash equivalents at begin of the year	**951**	683	**673**	684
Translation differences	**-72**	140	**-27**	184
Cash and cash equivalents at end of the period	**894**	673	**894**	673

Operating cash flow statement

SEK million	2007 Q 4	2006 Q 4	2007 12 Mon	2006 12 Mon
Business activities				
Operating profit	**1 033**	840	**2 282**	1 936
Restructuring costs	**27**	-2,0	**257**	45
Adjustment for items not included in cash flow	**214**	78	**694**	277
	1 274	916	**3 233**	2 258
Changes in operating capital				
Stock-in-trade	**247**	217	**-341**	-75
Rental equipment	**-43**	-9	**-168**	-11
Current receivables	**-1 106,0**	-794	**-458**	-484
Current liabilities	**171**	111	**287**	451
Operating cash flow	**543**	441	**2 553**	2 139
Restructuring cost cash generated	**-102**	-10	**-190**	-45
Operating cash flow after restructuring cost	**441**	431	**2 363**	2 094

Consolidated Net interest-bearing debt

SEK million	2007 31 Dec	2006 31 Dec
Debt to credit institutions	**9 454**	4 609
Provisions for pensions, interest-bearing	**1 805**	1 639
Less liquid funds	**-894**	-673
Net interest-bearing debt	**10 365**	5 575

Changes to shareholders' equity

SEK million	2007 31 Dec	2006 31 Dec
Shareholders' equity – opening balance	**6 005**	5 381
Dividend distributed	**-444**	-404
Dividend to minority	**–**	-1
Change of reserve hedge accounting	**-58**	160
Change of minority	**–**	-51
Translation differences	**-141**	-339
Net profit	**1 261**	1 259
Shareholders' equity – closing balance	**6 623**	6 005
Attributable to:		
Parent company's shareholders	**6 598**	5 983
Minority interest	**25**	22
Total shareholders' equity	**6 623**	6 005

Key figures

	2007 Q 4	2006 Q 4	*Change*	2005 Q 4	**2007** 12 Mon	2006 12 Mon	*Change*	2005 12 mån
Orders received, SEK million	**4 585**	3 660	*25,3%*	3 557	**16 519**	13 316	*24,1%*	12 225
adjusted for currency flucs.& corp.acqs			*5,5%*				*5,4%*	
Net sales, SEK million	**5 157**	3 995	*29,1%*	3 889	**16 445**	13 001	*26,5%*	11 880
adjusted for currency flucs.& corp.acqs			*12,2%*				*7,9%*	
EBITA before restructuring- and integration costs	**1 096**	848	*29,2%*	750	**2 678**	2 018	*32,7%*	1 831
EBITA margin before restructuring- and integration costs	**21,3%**	21,2%	*0,1%*	19,3%	**16,3%**	15,5%	*0,8%*	15,4%
Restructuring and integration costs	**27**	-2	*0,0%*	–	**257**	45	*0,0%*	–
EBITA	**1 069**	850	*25,8%*	750	**2 421**	1 973	*22,7%*	1 831
EBITA margin	**20,7%**	21,3%	*-0,6%*	19,3%	**14,7%**	15,2%	*-0,5%*	15,4%
Earnings per share after full tax, SEK	**3,17**	2,83	*12,0%*	2,45	**6,24**	6,21	*0,5%*	5,64
Nmb of shares, thousands	**201 874**	201 874		201 874	**201 874**	201 874		201 874
Operating capital, SEK million					**10 778**	10 217	*5,5%*	9 571
Return on operating capital, per cent					**19,7%**	19,2%	*0,5%*	18,5%
Return on equity, per cent					**20,3%**	22,6%	*-2,3%*	24,3%
Net debt/equity ratio, multiple					**1,57**	0,93	*0,64*	0,95
Interest cover, multiple					**4,3**	9,0	*-4,7*	8,3
Equity/assets ratio, per cent					**28,8%**	37,8%	*-9,0%*	37,0%
Equity per share, SEK					**32,68**	29,64	*10,3%*	26,29
Number of employees at the period's (					**10 358**	7 531	*37,5%*	7 362

Income statement for the parent company

M kr	2007 12 Mon	2006 12 Mon
Administrative expenses	**-67**	-87
Operating profit	**-67**	-87
Financial net	**542**	580
Profit after financial items	**475**	493
Appropriations	**–**	12
Profit vefore tax	**475**	505
Taxes	**96**	-52
Net profit	**571**	453

Balance sheet for the parent company

Assets SEK million	2007 31 Dec	2006 31 Dec
Tangible fixed assets	**12**	15
Shares in group companies	**4 120**	3 453
Long-term financial receivables	**41**	55
Deferred tax asset	**86**	–
Receivable from group companies	**13 033**	8 468
Short-term receivables	**65**	59
Total assets	**17 357**	12 050

Shareholders' equity & Liabilities		
Shareholders' equity	**3 829**	3 649
Long-term liabilities	**7 523**	3 818
Current liabilities	**6 005**	4 583
Total Equity & Liabilities	**17 357**	12 050

Information about the Parent Company

Major changes in the Parent Company's financial position for the reporting period are attributable to investments in subsidiaries, particularly Huntleigh.

Companies acquired in 2007

Huntleigh Technology Plc

As at 31 December 2006, the Getinge Group had acquired 21,52 % of the shares in Huntleigh Technology PLC. The remaining shares were aquired in January 2007. Huntleigh operates in the areas of special wound-care mattresses, beds for intensive, specialist and geriatric care, compression products that prevent the occurrence of deep vein thromboses and facilitate the treatment of lymphodema and pressure sores, as well as equipment for embryonic and cardiocirculatory diagnostics. The acquisition was reported in accordance with the purchase method. The total purchase price amounted to approximately GBP 412m (SEK 5 631m). Costs in connection with the acquistion amounted to GBP 4,8m (SEK 66m).

Acquired net assets and goodwill in connection with the acquisition

Net assets	Balance sheet at time of acquisition	Adjustments to fair value	Fair value
Intangible assets	93	1 299	1 392
Tangible fixed assets	772	49	821
Stock-in-trade	454		454
Other current assets	849		849
Cash and cash equivalents	118		118
Provisions	-180		-180
Deferred tax liabilities	126	-456	-330
Short-term liabilities	-923		-923
	1 309	892	2 201
Goodwill			3 430
Total acquisition with cash and cash equivalents			**5 631**

Net outflow of cash and cash equivalents due to acquisition

Cash and cash equivalents paid for acquisition	-5 631
Cash and cash equivalents in the acquired company at time of acquisitior	118
	-5 513

Goodwill generated in connection with the transaction is principally attributable to synergies in terms of customer stock, geography, production and selling and distribution.

Had the acquisition date for Huntleigh Technology Plc been the beginning of 2007, the total revenue of the Getinge group for the year ended 31 December 2007 would have been SEK 16 692m and the operating profit would have been SEK 2 299m.

Due to the significant integration of the Huntleigh and Getinge businesses during 2007, it is impracticable to disclose the profit for only the acquired entity since the acquisition date.

NC Nielsen Equipment A/S

On 31 October 2007 the Getinge group acquired 100% of the total share capital in the Danish company NC Nielsen Equipment A/S at a purchase price of DKK 18m (SEK 23m). The acquisition is reported in accordance with the purchase method.

Acquired net assets and goodwill in connection with the acquisition

Net assets	**Balance sheet at time of acquisition**	**Adjustments to fair value**	**Fair value**
Stock-in-trade	4		4
Other current assets	4		4
Short-term liabilities	-1		-1
	7	0	7
Goodwill			16
Total acquisition with cash and cash equivalents			**23**

Net outflow of cash and cash equivalents due to acquisition

Cash and cash equivalents paid for acquisition	-23
Cash and cash equivalents in the acquired company at time of acquisitior	0
	-23

Goodwill generated in connection with the transaction is principally attributable to additional sales of Medical Systems products in Denmark.

In the period following the acquistion, NC Nielsen Equipment A/S contributed SEK 7m to Group sales and SEK 1m to consolidated profit before tax.

NC Nielsen Equipment A/S has been consolidated in the group from since November 2007.

As at 31 December 2007, the purchase price allocation process was not finalised and therefore the above figures may be subject to change.

Acquisition after balance-sheet date

Getinge acquired Boston Scientific's cardiac and vascular divisions on 7 January. Getinge paid a total of USD 750 million (SEK 4,850 million) for the two divisions on a debt-free basis (Enterprise value). The divisions will be consolidated in the Getinge Group from 1 January 2008.

Since the transaction was completed two to three weeks ago, a complete account of the net assets and the distribution of the purchase consideration are not provided in this report.

Definitions

EBIT	Operating profit
EBITA	Operating profit before amortisation of intangible assets identified in conjunction with corporate acquisitions.
BRIC	Brazil, Russia, India, China

Auditors’ review report

Introduction

We have performed a review of the Year-end Report (interim report) for Getinge AB at 31 December 2007 and the accompanying reports on the income statement and balance sheet, changes in shareholders’ equity and the change in cash flow for the twelve-month period ending at that date and a summary of the key accounting policies and other supplementary disclosures. It is the responsibility of the President and the Board of Directors to prepare and present fair interim financial information in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express an opinion on this interim financial information based on our review.

The focus and scope of the review

We have performed our review in accordance with the Standard on Review Engagements SÖG 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

Review of Interim Financial Information Performed by the Independent Auditor of the Entity

A review consists of making inquiries, primarily of persons responsible for financial and accounting issues, performing an analytical review and carrying out other review measures. A review has a different focus and a substantially limited scope compared with the focus and scope of an audit in accordance with Swedish Auditing Standards and good auditing practice in general. The review measures carried out in a review do not enable us to obtain a level of assurance that would make us aware of all the significant matters which could have been identified if an audit had been performed. The opinion expressed on the basis of a review does not therefore provide the same level of assurance as a conclusion expressed on the basis of an audit.

Conclusion

Based on our review, no circumstances have emerged that give us reason to assume that the enclosed interim report has not, in all material aspects, been prepared for the Group in accordance with IAS 34 and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act.

Gothenburg, 28 January 2008

DELOITTE AB

Jan Nilsson
Authorised Public Accountant